683 Capital Management’s Cartesian Therapeutics RNAC Stock Holding History

683 Capital Management’s Portfolio RNAC Stock Details RNAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.03M	Buy	330,000 +50,000	+18%	+$356K	0.11%	106
2025 Q4	$2.02M	Buy	280,000 +50,000	+22%	+$404K	0.09%	107
2025 Q3	$2.35M	Buy	230,000 +11,000	+5%	+$124K	0.12%	104
2025 Q2	$2.28M	Buy	219,000 +69,000	+46%	+$735K	0.15%	101
2025 Q1	$1.98M	Buy	150,000 +25,000	+20%	+$447K	0.14%	108
2024 Q4	$2.24M	Buy	125,000 +49,569	+66%	+$1M	0.14%	88
2024 Q3	$1.22M	Buy	+75,431	New	+$1.18M	0.09%	99
2021 Q1	–	Sell	-23,821	Closed	-$2.17M	–	224
2020 Q4	$2.17M	Hold	23,821	–	–	0.1%	97
2020 Q3	$1.77M	Hold	23,821	–	–	0.13%	85
2020 Q2	$2.03M	Hold	23,821	–	–	0.16%	78
2020 Q1	$1.72M	Buy	+23,821	New	+$2.3M	0.2%	75

Other funds holding RNAC

Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PFM

Privium Fund Management Amsterdam, Netherlands $480M AUM 77.45% 1-Year Est. Return

683 Capital Management's RNAC Position: Q1 2026 in Review

683 Capital Management increased its Cartesian Therapeutics (RNAC) stake by 18% in Q1 2026, buying an estimated $356K and bringing the position to 330,000 shares worth $2.03M. The position accounts for 0.11% of the portfolio, ranked #106.

683 Capital Management first reported a position in RNAC in Q1 2020 and has held it in 11 quarters since. The position peaked at $2.35M in Q3 2025. 83 funds tracked by Wall St. Rank hold RNAC as of Q1 2026.

683 Capital Management held 330,000 shares of Cartesian Therapeutics worth $2.03M as of Q1 2026.
683 Capital Management bought 50,000 Cartesian Therapeutics shares in Q1 2026, an estimated $356K.
Cartesian Therapeutics made up 0.11% of 683 Capital Management's portfolio in Q1 2026, its #106 holding.
683 Capital Management first reported a position in Cartesian Therapeutics in Q1 2020 and has held it in 11 quarters since.
683 Capital Management's Cartesian Therapeutics position peaked at $2.35M in Q3 2025.
83 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q1 2026.

Based on 683 Capital Management's 13F filing for Q1 2026, filed 15 May 2026.